<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03738319</url>
  </required_header>
  <id_info>
    <org_study_id>EOC-EXOSOME</org_study_id>
    <nct_id>NCT03738319</nct_id>
  </id_info>
  <brief_title>Non-coding RNA in the Exosome of the Epithelia Ovarian Cancer</brief_title>
  <official_title>Non-coding RNA in the Exosome of the Epithelia Ovarian Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lei Li</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking Union Medical College Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to analyze the expression of micro-RNA (miRNA) and long non-coding RNA
      (lncRNA) by next-generation sequencing in patients with high grade serous ovarian cancer
      (HGSOC) and benign gynecologic diseases. The candidate miRNA/lncRNA will be validated as
      biomarker for the detection and prognosis of HGSOC.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 10, 2018</start_date>
  <completion_date type="Anticipated">November 23, 2019</completion_date>
  <primary_completion_date type="Anticipated">November 23, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Differential expression of miRNA/lncRNA</measure>
    <time_frame>One year</time_frame>
    <description>Differential expression of micro-RNA (miRNA) and long non-coding RNA (lncRNA) will be compared between HGSOC group and control group, hence candidate miRNA/lncRNA will be validated as biomarker for the detection and prognosis of HGSOC.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>Five years</time_frame>
    <description>The progression-free survival of HGSOC patients will be compared between differential expressed candidate miRNA/lncRNA after they have completed debulking surgeries and adjuvant chemotherapy.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">160</enrollment>
  <condition>High Grade Serous Carcinoma</condition>
  <condition>Ovarian Cancer</condition>
  <condition>Exosomes</condition>
  <condition>Prognosis</condition>
  <condition>Early Diagnosis</condition>
  <arm_group>
    <arm_group_label>HGSOC group</arm_group_label>
    <description>This group includes patients of high grade serous ovarian cancer (HGSOC).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <description>This group includes patients of benign gynecologic diseases as control.</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Sequencing of miRNA/lncRNA</intervention_name>
    <description>Next generation sequencing of micro-RNA (miRNA) and long non-coding RNA (lncRNA)</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>HGSOC group</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      An 8 ml peripheral venous blood will be collected from the participants before and after
      interventions (i.e. surgery and/or chemotherapy)
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        There will be 20 patients of high grade serous ovarian cancer (HGSOC) and 20 patients with
        benign gynecologic diseases, whose data will be applied for construction of diagnostic
        model of miRNA/lncRNA from exosome. There will be 120 patients suspected of HGSOC, whose
        data will be applied for validation of such diagnosis model.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed primary high grade serous ovarian cancer

          -  Willing to accepted debulking surgeries and adjuvant chemotherapy

          -  Good performance status

          -  Aged 18 years or older

          -  Signed an approved informed consents

        Exclusion Criteria:

          -  Not meeting all of the inclusion criteria
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lei Li, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking Union Medical College Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lei Li, M.D.</last_name>
    <phone>13911988831</phone>
    <phone_ext>86</phone_ext>
    <email>lileigh@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Lei Li</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lei Li, MD</last_name>
      <phone>008613911988831</phone>
      <email>lileigh@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>November 8, 2018</study_first_submitted>
  <study_first_submitted_qc>November 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 13, 2018</study_first_posted>
  <last_update_submitted>November 9, 2018</last_update_submitted>
  <last_update_submitted_qc>November 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Peking Union Medical College Hospital</investigator_affiliation>
    <investigator_full_name>Lei Li</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
    <mesh_term>Cystadenocarcinoma, Serous</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All data will be available to all researchers.</ipd_description>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>All data will be available to all researchers once related papers have been accepted publicly, and will be available for ever.</ipd_time_frame>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

